Research programme: ERN1 protein inhibitors - MannKind Corporation

Drug Profile

Research programme: ERN1 protein inhibitors - MannKind Corporation

Alternative Names: Inositol requiring enzyme-1 inhibitor; IRE-1α inhibitor; MKC 204; Mkc 8866; MKC-3946

Latest Information Update: 29 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MannKind Corporation
  • Class Small molecules
  • Mechanism of Action ERN1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Multiple myeloma

Most Recent Events

  • 22 Jun 2017 Preclinical trials in Acute lymphoblastic leukaemia in USA (unspecified route)
  • 22 Jun 2017 Pharmacodynamics data from preclinical trials in Acute lymphoblastic leukaemia were presented at the 22nd Congress of the European Haematology Association (EHA-2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-myeloma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top